WallStreetZenWallStreetZen

NASDAQ: RVNC
Revance Therapeutics Inc Earnings & Revenue

RVNC past revenue growth

How has RVNC's revenue growth performed historically?
Company
76.55%
Industry
169.3%
Market
17.86%
RVNC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RVNC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RVNC's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RVNC earnings and revenue history

Current Revenue
$234.0M
Current Earnings
-$324.0M
Current Profit Margin
-138.4%

RVNC Return on Equity

Current Company
N/A
Current Industry
-63.4%
Current Market
188%

Be the first to know when RVNC announces earnings.

RVNC Return on Assets

Current Company
-60.1%
Current Industry
3.2%
RVNC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RVNC Return on Capital Employed

Current Company
-78.19%
Current Industry
19.9%
RVNC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RVNC vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RVNC$234.04M-$290.64M-$323.99M+128.84%N/A
OCS$1.00M-$98.97M-$100.91M-1.76%N/A
JSPR$0.00-$62.94M-$64.47MN/AN/A
TBPH$57.42M-$40.77M-$55.19M-1.00%N/A
IVVD$0.00-$167.85M-$169.56MN/AN/A

RVNC earnings dates

Next earnings date
May 6, 2024

Revance Therapeutics Earnings & Revenue FAQ

What were RVNC's earnings last quarter?

On Invalid Date, Revance Therapeutics (NASDAQ: RVNC) reported Q4 2023 earnings per share (EPS) of -$0.63, up 66.84% year over year. Total Revance Therapeutics earnings for the quarter were -$55.70 million. In the same quarter last year, Revance Therapeutics's earnings per share (EPS) was -$1.90.

If you're new to stock investing, here's how to buy Revance Therapeutics stock.

What was RVNC's earnings growth in the past year?

As of Q1 2024, Revance Therapeutics's earnings has grown year over year. Revance Therapeutics's earnings in the past year totalled -$323.99 million.

What is RVNC's earnings date?

Revance Therapeutics's earnings date is Invalid Date. Add RVNC to your watchlist to be reminded of RVNC's next earnings announcement.

What was RVNC's revenue last quarter?

On Invalid Date, Revance Therapeutics (NASDAQ: RVNC) reported Q4 2023 revenue of $69.80 million up 39.82% year over year. In the same quarter last year, Revance Therapeutics's revenue was $49.92 million.

What was RVNC's revenue growth in the past year?

As of Q1 2024, Revance Therapeutics's revenue has grown 76.55% year over year. This is 92.75 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Revance Therapeutics's revenue in the past year totalled $234.04 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.